BACKGROUND: We studied potential risk factors for lymphedema in a contemporary population of older breast cancer patients. METHODS: Telephone surveys were conducted among women (65-89 years) identified from Medicare claims as having initial breast cancer surgery in 2003. Lymphedema was classified by self-report. Surgery and pathology information was obtained from Medicare claims and the state cancer registries. RESULTS: Of 1,338 patients treated by 707 surgeons, 24% underwent sentinel lymph node biopsy (SLNB) and 57% axillary lymph node dissection (ALND). At a median of 48 months postoperatively, 193 (14.4%) had lymphedema. Lymphedema developed in 7% of the 319 patients who underwent SLNB and in 21% of the 759 patients who underwent ALND. When controlling for patient age, tumor size, type of breast cancer, type of breast and axillary surgery, receipt of radiation, chemotherapy, and hormonal therapy, and surgeon case volume, the independent predictors of lymphedema were removal of more than five lymph nodes [odds ratio (OR) 4.68-5.61, 95% confidence interval (CI) 1.36-19.74 for 6-15 nodes; OR 10.50, 95% CI 2.88-38.32 for >15 nodes] and presence of lymph node metastases (OR 1.98, 95% CI 1.21-3.24). CONCLUSIONS: Four years postoperatively, 14% of a contemporary, population-based cohort of elderly breast cancer survivors had self-reported lymphedema. In this group of predominantly community-based surgeons, the number of lymph nodes removed is more predictive of lymphedema rather than whether SLNB or ALND was performed. As more women with breast cancer undergo only SLNB, it is essential that they still be counseled on their risk for lymphedema.
BACKGROUND: We studied potential risk factors for lymphedema in a contemporary population of older breast cancerpatients. METHODS: Telephone surveys were conducted among women (65-89 years) identified from Medicare claims as having initial breast cancer surgery in 2003. Lymphedema was classified by self-report. Surgery and pathology information was obtained from Medicare claims and the state cancer registries. RESULTS: Of 1,338 patients treated by 707 surgeons, 24% underwent sentinel lymph node biopsy (SLNB) and 57% axillary lymph node dissection (ALND). At a median of 48 months postoperatively, 193 (14.4%) had lymphedema. Lymphedema developed in 7% of the 319 patients who underwent SLNB and in 21% of the 759 patients who underwent ALND. When controlling for patient age, tumor size, type of breast cancer, type of breast and axillary surgery, receipt of radiation, chemotherapy, and hormonal therapy, and surgeon case volume, the independent predictors of lymphedema were removal of more than five lymph nodes [odds ratio (OR) 4.68-5.61, 95% confidence interval (CI) 1.36-19.74 for 6-15 nodes; OR 10.50, 95% CI 2.88-38.32 for >15 nodes] and presence of lymph node metastases (OR 1.98, 95% CI 1.21-3.24). CONCLUSIONS: Four years postoperatively, 14% of a contemporary, population-based cohort of elderly breast cancer survivors had self-reported lymphedema. In this group of predominantly community-based surgeons, the number of lymph nodes removed is more predictive of lymphedema rather than whether SLNB or ALND was performed. As more women with breast cancer undergo only SLNB, it is essential that they still be counseled on their risk for lymphedema.
Authors: A M Leitch; A G Meek; R A Smith; M Boris; P Bourgeois; S Higgins; P I Pressman; J Stevens; R E Stevens Journal: Cancer Date: 1998-12-15 Impact factor: 6.860
Authors: T Kuehn; W Klauss; M Darsow; S Regele; F Flock; C Maiterth; R Dahlbender; I Wendt; R Kreienberg Journal: Breast Cancer Res Treat Date: 2000-12 Impact factor: 4.872
Authors: Anthony Lucci; Linda Mackie McCall; Peter D Beitsch; Patrick W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukumal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2007-05-07 Impact factor: 44.544
Authors: Joan M Neuner; Mary Ann Gilligan; Rodney Sparapani; Purushottam W Laud; David Haggstrom; Ann B Nattinger Journal: Cancer Date: 2004-09-15 Impact factor: 6.860
Authors: John A Olson; Linda M McCall; Peter Beitsch; Pat W Whitworth; Douglas S Reintgen; Peter W Blumencranz; A Marilyn Leitch; Sukamal Saha; Kelly K Hunt; Armando E Giuliano Journal: J Clin Oncol Date: 2008-07-20 Impact factor: 44.544
Authors: Marilyn L Kwan; Jeanne Darbinian; Kathryn H Schmitz; Rebecca Citron; Paula Partee; Susan E Kutner; Lawrence H Kushi Journal: Arch Surg Date: 2010-11
Authors: Tina W F Yen; Purushottam W Laud; Liliana E Pezzin; Emily L McGinley; Erica Wozniak; Rodney Sparapani; Ann B Nattinger Journal: Med Care Date: 2018-01 Impact factor: 2.983
Authors: Shayna L Showalter; Justin C Brown; Andrea L Cheville; Carla S Fisher; Dahlia Sataloff; Kathryn H Schmitz Journal: Ann Surg Oncol Date: 2012-10-03 Impact factor: 5.344
Authors: Sally A Dominick; Loki Natarajan; John P Pierce; Hala Madanat; Lisa Madlensky Journal: Support Care Cancer Date: 2014-02-14 Impact factor: 3.603
Authors: Sharon L Kilbreath; Mi-Joung Lee; Kathryn M Refshauge; Jane M Beith; Leigh C Ward; J M Simpson; D Black Journal: Support Care Cancer Date: 2013-03-15 Impact factor: 3.603